MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
2.965
+0.095
+3.31%
Opening 14:53 07/20 EDT
OPEN
2.860
PREV CLOSE
2.870
HIGH
3.064
LOW
2.860
VOLUME
36.54K
TURNOVER
--
52 WEEK HIGH
5.74
52 WEEK LOW
1.110
MARKET CAP
37.83M
P/E (TTM)
-2.0489
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LTRN last week (0713-0717)?
Weekly Report · 10h ago
New to The Street(R) to Broadcast Show #762 Tonight on Bloomberg Television at 6:30 PM ET, Featuring Envoy Medical (NASDAQ:COCH), AlphaCompute (NASDAQ:ALP), RHINO Bitcoin (OTC PINK:RHNO), and Big Sky Industrial (NASDAQ:BSIN)
Barchart · 2d ago
Lantern Pharma publishes investor presentation on AI-driven oncology drug development platform, pipeline programs
PUBT · 6d ago
Weekly Report: what happened at LTRN last week (0706-0710)?
Weekly Report · 07/13 09:15
New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group
Barchart · 07/11 11:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/08 17:05
Lantern Pharma launches ZetaOmics computational-biology module
TipRanks · 07/08 11:35
Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist Platform
Benzinga · 07/08 11:33
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.